KR102575872B1 - 마이코박테리아 감염을 치료하는 데에 사용하기 위한 산페트리넴 또는 그의 염 또는 에스테르 - Google Patents

마이코박테리아 감염을 치료하는 데에 사용하기 위한 산페트리넴 또는 그의 염 또는 에스테르 Download PDF

Info

Publication number
KR102575872B1
KR102575872B1 KR1020197032729A KR20197032729A KR102575872B1 KR 102575872 B1 KR102575872 B1 KR 102575872B1 KR 1020197032729 A KR1020197032729 A KR 1020197032729A KR 20197032729 A KR20197032729 A KR 20197032729A KR 102575872 B1 KR102575872 B1 KR 102575872B1
Authority
KR
South Korea
Prior art keywords
mycobacterium
tuberculosis
pharmaceutically acceptable
pharmaceutical composition
ester prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197032729A
Other languages
English (en)
Korean (ko)
Other versions
KR20200003816A (ko
Inventor
다비드 바로스 아기레
로베르트 에이치. 바테스
루벤 곤살레스 델 리오
알폰소 멘도사 로사나
산티아고 라몬 가르시아
Original Assignee
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 filed Critical 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드
Publication of KR20200003816A publication Critical patent/KR20200003816A/ko
Application granted granted Critical
Publication of KR102575872B1 publication Critical patent/KR102575872B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D463/00—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D463/10—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D463/12—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals attached in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197032729A 2017-05-08 2018-05-04 마이코박테리아 감염을 치료하는 데에 사용하기 위한 산페트리넴 또는 그의 염 또는 에스테르 Active KR102575872B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382255 2017-05-08
EP17382255.2 2017-05-08
PCT/EP2018/061615 WO2018206466A1 (en) 2017-05-08 2018-05-04 Sanfetrinem or a salt or ester thereof for use in treating mycobacterial infection

Publications (2)

Publication Number Publication Date
KR20200003816A KR20200003816A (ko) 2020-01-10
KR102575872B1 true KR102575872B1 (ko) 2023-09-08

Family

ID=58709903

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197032729A Active KR102575872B1 (ko) 2017-05-08 2018-05-04 마이코박테리아 감염을 치료하는 데에 사용하기 위한 산페트리넴 또는 그의 염 또는 에스테르

Country Status (22)

Country Link
US (1) US11253500B2 (https=)
EP (1) EP3621609B1 (https=)
JP (1) JP7123074B2 (https=)
KR (1) KR102575872B1 (https=)
CN (1) CN110869016B (https=)
AU (1) AU2018265192B2 (https=)
BR (1) BR112019023322B1 (https=)
CA (1) CA3060396A1 (https=)
CY (1) CY1125546T1 (https=)
DK (1) DK3621609T3 (https=)
ES (1) ES2925215T3 (https=)
HR (1) HRP20221212T1 (https=)
HU (1) HUE059818T2 (https=)
LT (1) LT3621609T (https=)
PL (1) PL3621609T3 (https=)
PT (1) PT3621609T (https=)
RS (1) RS63461B1 (https=)
RU (1) RU2757272C2 (https=)
SI (1) SI3621609T1 (https=)
SM (1) SMT202200400T1 (https=)
WO (1) WO2018206466A1 (https=)
ZA (1) ZA201906810B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111184718A (zh) * 2018-11-15 2020-05-22 鲁南制药集团股份有限公司 法罗培南在制备治疗初治病原学阳性肺结核药物中的用途
CN117462551B (zh) * 2023-12-27 2024-05-17 深圳国家感染性疾病临床医学研究中心 茚地那韦和/或其衍生物在制备抗结核药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046845A1 (en) 2014-09-25 2016-03-31 Manu Chaudhary Stealth, targeted nanoparticles (stn) for oral drug delivery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ435990A3 (cs) 1989-09-08 1999-11-17 Glaxo S.P.A. Kyselina 10-(1-hydroxyethyl)-11-oxo-1-azatricyklo/7,2,0,03,8/-undec-2en-2-karboxylová a její deriváty, způsob jejich výroby, použití pro výrobu farmaceutických prostředků a farmaceutické prostředky s jejich obsahem
GB9018330D0 (en) * 1990-08-21 1990-10-03 Glaxo Spa Heterocyclic compounds
JP3151215B2 (ja) 1990-08-21 2001-04-03 グラクソ・ソシエタ・ペル・アツイオーニ 複素環式化合物
GB9104769D0 (en) 1991-03-07 1991-04-17 Glaxo Spa Heterocyclic compounds
GB9305813D0 (en) 1993-03-20 1993-05-05 Glaxo Spa Chemical process
EP2085084A1 (en) * 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics
EP2135871A1 (en) * 2008-06-18 2009-12-23 LEK Pharmaceuticals D.D. New trinem antibiotics and inhibitors of beta-lactamases
MA41494B1 (fr) * 2015-02-12 2020-10-28 Glaxosmithkline Ip No 2 Ltd Composés benzoxaborole substitués en position 4 et utilisations associées

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046845A1 (en) 2014-09-25 2016-03-31 Manu Chaudhary Stealth, targeted nanoparticles (stn) for oral drug delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clinical Microbiology and Infection, Vol.3, Supplement 2, p.169, P706 (1995.07.01)*

Also Published As

Publication number Publication date
ES2925215T3 (es) 2022-10-14
RU2019139864A (ru) 2021-06-09
WO2018206466A1 (en) 2018-11-15
US20200289462A1 (en) 2020-09-17
EP3621609A1 (en) 2020-03-18
JP2020519592A (ja) 2020-07-02
AU2018265192B2 (en) 2021-06-17
KR20200003816A (ko) 2020-01-10
JP7123074B2 (ja) 2022-08-22
BR112019023322B1 (pt) 2023-11-14
CA3060396A1 (en) 2018-11-15
CY1125546T1 (el) 2026-02-25
BR112019023322A2 (pt) 2020-06-16
ZA201906810B (en) 2021-03-31
US11253500B2 (en) 2022-02-22
EP3621609B1 (en) 2022-07-27
HRP20221212T1 (hr) 2022-12-09
SI3621609T1 (sl) 2022-10-28
PT3621609T (pt) 2022-08-24
AU2018265192A1 (en) 2019-11-07
PL3621609T3 (pl) 2022-11-14
SMT202200400T1 (it) 2022-11-18
DK3621609T3 (da) 2022-08-29
RU2757272C2 (ru) 2021-10-12
CN110869016B (zh) 2023-09-12
HUE059818T2 (hu) 2022-12-28
CN110869016A (zh) 2020-03-06
RS63461B1 (sr) 2022-08-31
RU2019139864A3 (https=) 2021-06-28
LT3621609T (lt) 2022-10-10

Similar Documents

Publication Publication Date Title
Dutta et al. Mycobacterial protein tyrosine phosphatases A and B inhibitors augment the bactericidal activity of the standard anti-tuberculosis regimen
WO2014014845A1 (en) Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases
CA3001309A1 (en) Combination antibacterial composition and short-course antibacterial regimen
KR102575872B1 (ko) 마이코박테리아 감염을 치료하는 데에 사용하기 위한 산페트리넴 또는 그의 염 또는 에스테르
CN118986984B (zh) 一种抗分枝杆菌感染的药物组合物
CA2624497C (en) Antituberculosis drug combination comprising oxazole compounds
CN108883114B (zh) 抗结核药物
JP2015536949A (ja) 細菌感染症のための抗生物質を用いる方法および組成物
US10842874B2 (en) Sensitization of bacterial cells to quinolone antibiotics
JP2020519592A5 (https=)
WO2018019031A1 (en) A pharmaceutical composition comprising an ionophore and a beta-lactam antibiotic and use thereof
CN121604963A (zh) 包含贝达喹啉、普托马尼或德拉马尼的至少三种抗生素与细胞色素bc1抑制剂的组合产品及其在治疗分枝杆菌感染中的用途
CN120379693A (zh) 一种药物组合及应用
Phillips et al. Research Article Antimycobacterial Activities of Novel 5-(1H-1, 2, 3-Triazolyl) Methyl Oxazolidinones
Adamovich Anti-Tuberculosis Drug Discovery by Bioluminescence-Based Screening of a Protein Kinase Inhibitor Library Honors Research Thesis
KR20110127219A (ko) 결핵 치료용 화합물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191105

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210430

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230302

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230701

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230904

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230905

End annual number: 3

Start annual number: 1

PG1601 Publication of registration